<DOC>
	<DOCNO>NCT01691534</DOCNO>
	<brief_summary>The trial evaluate extend bactericidal activity 14 consecutive day oral administration TMC207 plus PA-824 plus Pyrazinamide plus Clofazimine , TMC207 plus PA-824 plus Pyrazinamide , TMC207 plus PA-824 plus Clofazimine alone , TMC207 plus Pyrazinamide plus Clofazimine , Pyrazinamide alone , Clofazimine alone , standard first line TB treatment per South African TB Guidelines ( Rifafour e-275 ) determine rate change log CFU per ml sputum time period Day 0-14 participant smear positive pulmonary tuberculosis ( TB ) . A control group receive standard treatment .</brief_summary>
	<brief_title>Evaluation Early Bactericidal Activity Pulmonary Tuberculosis With Clofazimine ( C ) -TMC207 ( J ) -PA-824 ( Pa ) -Pyrazinamide ( Z )</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Bedaquiline</mesh_term>
	<mesh_term>Diarylquinolines</mesh_term>
	<mesh_term>Clofazimine</mesh_term>
	<criteria>1 . Provide write , informed consent prior trialrelated procedure include HIV testing . 2 . Male female , age 18 65 year inclusive . 3 . Body weight ( light clothing shoe ) 40 90 kg , inclusive . 4 . Newly diagnose , previously untreated , sputum smearpositive pulmonary TB . 5 . A chest Xray picture opinion Investigator compatible TB . 6 . Sputum positive GeneXpert TB Smear TB clinic site initial diagnosis 7 . Sputum positive direct microscopy acidfast bacillus ( least 1+ IUATLD/WHO scale ) . 8 . Ability produce adequate volume sputum estimate spot assessment ( estimate 10 ml overnight production ) . 9 . Be nonchildbearing potential use effective method birth control define : Nonchildbearing potential : 1 . Subject Not heterosexually active practice sexual abstinence 2 . Female subject/sexual bilateral oophorectomy , bilateral tubal ligation , and/or hysterectomy postmenopausal history menses least 12 consecutive month ) 3 . Male subject/sexual partner vasectomise bilateral orchidectomy minimally three month prior screen Effective birth control method : 1 . Double barrier method include male condom , diaphragm , cervical cap , female condom 2 . Barrier method combine hormone base contraceptive intrauterine device female partner willing continue practice birth control method throughout treatment 12 week ( male participant ) 6 month ( female participant ) last dose study medication discontinuation study medication case premature discontinuation ( Note : Hormonebased contraception alone may reliable take IMP ; therefore , hormonebased contraceptive alone use female participant prevent pregnancy ) . 1 . Evidence clinically significant ( judged investigator ) , metabolic , gastrointestinal , cardiovascular , musculoskeletal , ophthalmological , pulmonary , neurological , psychiatric endocrine disease , malignancy , abnormality ( indication study ) include malaria . 2 . Poor general condition delay treatment tolerate per discretion Investigator . 3 . A history previous TB . 4 . Clinically significant evidence extrathoracic TB ( miliary TB , abdominal TB , urogenital TB , osteoarthritic TB , TB meningitis ) , judge Investigator . 5 . History allergy IMP related substance . 6 . Isoniazidresistant and/or Rifampicinresistant bacteria detect sputum specimen collect within pretreatment period test study laboratory . 7 . Known suspected , current history within past 2 year , alcohol drug abuse , , opinion Investigator , sufficient compromise safety cooperation participant . 8 . HIV infect participant : 1. CD4+ count &lt; 200 cells/µL ; 2. receive antiretroviral therapy medication within last 90 day ; 3. receive oral intravenous antifungal medication within last 90 day ; 4. AIDSdefining opportunistic infection malignancy ( except pulmonary TB ) . 9 . Having participate clinical study investigational agent within 8 week prior trial start . 10 . Significant cardiac arrhythmia require medication . 11 . Participants follow screening . For ECGs , central cardiology overread mean triplicate reading must use : 1 . Marked prolongation QT/QTc interval , e.g. , confirm demonstration QTcF ( Fridericia correction ) QTcB ( Bazett correction ) interval &gt; 450 m screening ; 2 . History additional risk factor Torsade de Pointes , e.g. , heart failure , hypokalemia , family history Long QT Syndrome ; 3 . Use concomitant medication prolong QT/QTc interval ( see exclusion criterion 19 disallowed medication ; 4 . Pathological Q wave ( define &gt; 40ms depth &gt; 0.40.5mV ) ; 5 . ECG evidence ventricular preexcitation ; 6 . ECG evidence complete incomplete leave bundle branch block right bundle branch block ; 7 . ECG evidence second third degree heart block ; 8 . Intraventricular conduction delay QRS duration &gt; 120ms ; 9 . Bradycardia define sinus rate &lt; 50bpm . 12 . Females pregnant , breastfeeding , plan conceive child within 6 month cessation treatment . Males plan conceive child within twelve week cessation treatment . 13 . Diabetes Mellitus require insulin . 14 . History lens opacity . 15 . For male , history clinically significant abnormality reproductive system . Specific Treatments 16 . Previously receive treatment Clofazimine , TMC207 PA824 . 17 . Treatment receive drug active MTB within 3 month prior Visit 1 ( e.g . isoniazid , ethambutol , amikacin , cycloserine , fluoroquinolones , rifabutin , rifampicin , streptomycin , kanamycin , paraaminosalicylic acid , rifapentine , pyrazinamide , thioacetazone , capreomycin , thioamides , metronidazole ) . 18 . Any disease condition use standard TB drug component contraindicate , include limited allergy TB drug , component IMP . 19 . Concomitant use drug know prolong QTc interval ( include amiodarone , bepridil , chloroquine , chlorpromazine , cisapride , clarithromycin , cyclobenzaprine , disopyramide dofetilide , domperidone , droperidol , erythromycin , halofantrine , haloperidol , ibutilide , levomethadyl , mesoridazine , methadone , pentamidine , pimozide , procainamide , quinidine , sotalol , sparfloxacin , thioridazine ) . 20 . Use drug substance within 30 day prior dose know strong inhibitor inducer cytochrome P450 enzyme ( quinidine , tyramine , ketoconazole , testosterone , quinine , gestodene , metyrapone , phenelzine , doxorubicin , troleandomycin , cyclobenzaprine , erythromycin , cocaine , furafylline , cimetidine , dextromethorphan ) . Exceptions may make participant receive 3 day less one drug substance , washout period administration IMP equivalent least 5 halflives drug substance . 21 . Use therapeutic agent know alter major organ function ( e.g. , barbiturate , opiate , phenothiazine , cimetidine ) within 30 day prior dose . Exceptions opiate pain killer use cough underlying disease may make investigator discretion . Based Laboratory Abnormalities 22 . Participants follow toxicity screen define enhanced Division Microbiology Infectious Disease ( DMID ) adult toxicity table ( November 2007 ) : 1. creatinine grade 2 great ( &gt; 1.5 time upper limit normal [ ULN ] ) ; 2. lipase grade 3 great ( &gt; 2.0 x ULN ) ; 3. hemoglobin grade 4 ( &lt; 6.5 g/dL ) ; 4. platelet grade 2 great ( 50x109 cells/L ) ; 5. serum potassium grade 2 great ( &lt; 3.5 mEq/L ) ; 6. aspartate aminotransferase ( AST ) grade 3 ( ≥3.0 x ULN ) exclude ; 7. alanine aminotransferase ( ALT ) grade 3 ( ≥3.0 x ULN ) exclude ; 8. alkaline phosphatase ( ALP ) grade 4 ( &gt; 8.0 x ULN ) exclude , grade 3 ( ≥3.0 x ULN ) must discuss sponsor Medical Monitor ; 9. total bilirubin grade 3 great ( &gt; 2.0 x ULN , &gt; 1.50 x ULN accompany increase liver function test ) exclude , grade 2 ( &gt; 1.50 x ULN , &gt; 1.25 x ULN accompany increase liver function test ) must discuss sponsor Medical Monitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>EBA</keyword>
	<keyword>PA824</keyword>
	<keyword>pretomanid</keyword>
	<keyword>TMC207</keyword>
</DOC>